Source:http://linkedlifedata.com/resource/pubmed/id/18006830
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
22
|
pubmed:dateCreated |
2007-11-16
|
pubmed:abstractText |
Melanoma incidence is increasing worldwide, and metastatic melanoma is almost completely resistant to every known therapy. New approaches to treating melanoma are urgently needed, and a greater understanding of the biology of melanoma invasion and metastasis will aid in their creation. A high proportion of invasive melanomas have a constitutively active Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK/ERK) signaling cascade; however, the downstream effectors of ERK signaling that contribute to melanoma invasion and metastasis are unknown. ERK signaling drives the production of the interstitial collagenase matrix metalloproteinase-1 (MMP-1), which is expressed specifically by invasive melanomas. Using short hairpin RNAs (shRNA) to knock down MMP-1 expression in a human melanoma cell line, we investigated the role of MMP-1 in melanoma metastasis in a xenograft model. Knockdown of MMP-1 had no effect on primary tumor growth, but reduction of MMP-1 expression significantly decreased the ability of the melanoma to metastasize from the orthotopic site in the dermis to the lung. Mechanistically, tumor cells expressing MMP-1 shRNAs had diminished collagenase activity, which is required for tumor cell invasion. Additionally, attenuation of MMP-1 expression reduced angiogenesis. These results show, for the first time, that targeted inhibition of MMP-1, a single effector of the Raf/MEK/ERK signaling cascade, prevents the progression of melanoma from a primary to metastatic tumor and, as such, may represent a useful therapeutic tool in controlling this disease.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1538-7445
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
67
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10849-58
|
pubmed:meshHeading |
pubmed-meshheading:18006830-Animals,
pubmed-meshheading:18006830-Cell Line, Tumor,
pubmed-meshheading:18006830-Collagenases,
pubmed-meshheading:18006830-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18006830-Female,
pubmed-meshheading:18006830-Humans,
pubmed-meshheading:18006830-Lung,
pubmed-meshheading:18006830-Matrix Metalloproteinase 1,
pubmed-meshheading:18006830-Melanoma,
pubmed-meshheading:18006830-Mice,
pubmed-meshheading:18006830-Mice, Nude,
pubmed-meshheading:18006830-Neoplasm Metastasis,
pubmed-meshheading:18006830-Neovascularization, Pathologic,
pubmed-meshheading:18006830-RNA Interference,
pubmed-meshheading:18006830-Signal Transduction
|
pubmed:year |
2007
|
pubmed:articleTitle |
RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis.
|
pubmed:affiliation |
Department of Biochemistry, Norris Cotton Cancer Center, Lebanon, New Hampshire, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|